A systematic review and meta-analysis of randomized controlled trials (RCTs) reveals only limited, low-quality evidence to support the use of pregabalin or gabapentin for the treatment of chronic low back pain (LBP). Results of the eight RCTs identified showed that gabapentin had a minimal benefit over placebo, and that pregabalin was inferior to other analgesics in relieving pain in adult patients with LBP of >3 months' duration. Use of the gabapentinoids was also associated with an increased risk of adverse events.
References
Shanthanna, H. et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 14, e1002369 (2017)
Rights and permissions
About this article
Cite this article
Onuora, S. Caution needed in use of gabapentinoids for LBP. Nat Rev Rheumatol 13, 570 (2017). https://doi.org/10.1038/nrrheum.2017.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.159